ECCRINE SQUAMOUS SYRINGOMETAPLASIA

This adverse event was reported 36 times

These drugs are most commonly taken by patients reporting ECCRINE SQUAMOUS SYRINGOMETAPLASIA:

# Drug Count
0 FLUDARABINE PHOSPHATE 7
1 BUSULFAN 6
2 CYTARABINE 4
3 VEMURAFENIB 4
4 CYCLOSPORINE 3
5 DOCETAXEL 3
6 DOCETAXEL ANHYDROUS 3
7 SIROLIMUS 3
8 TACROLIMUS 3
9 TACROLIMUS EXTENDED-RELEASE CAPSULES 3
See all common drugs associated with ECCRINE SQUAMOUS SYRINGOMETAPLASIA

ECCRINE SQUAMOUS SYRINGOMETAPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 GRANULOCYTE COLONY STIMULATING FACTOR 1 0.0005
1 BUSULFAN 6 0.0004
2 VEMURAFENIB 4 0.0003
3 SIROLIMUS 3 0.0002
4 FLUDARABINE PHOSPHATE 7 0.0002
5 MITOXANTRONE HYDROCHLORIDE 1 0.0002
6 ANTI-THYMOCYTE GLOBULIN (RABBIT) 1 0.0001
7 TERAZOSIN HYDROCHLORIDE 1 0.0001
8 CLADRIBINE 1 0.0001
9 ENCORAFENIB 1 0.0001
See all drugs enriched for association with ECCRINE SQUAMOUS SYRINGOMETAPLASIA

ECCRINE SQUAMOUS SYRINGOMETAPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Antimetabolite Immunosuppressant [EPC] 1 0.0000
1 Progesterone [EPC] 1 0.0000
2 Alkylating Drug [EPC] 6 0.0000
3 Microtubule Inhibitor [EPC] 4 0.0000
4 Calcineurin Inhibitor Immunosuppressant [EPC] 3 0.0000
5 Nucleoside Metabolic Inhibitor [EPC] 5 0.0000
6 Kinase Inhibitor [EPC] 9 0.0000
7 Platinum-based Drug [EPC] 3 0.0000
8 Purine Antimetabolite [EPC] 1 0.0000
9 Estrogen [EPC] 1 0.0000
See all drug classes enriched for association with ECCRINE SQUAMOUS SYRINGOMETAPLASIA